Survivorship Clinic for long-term survivors with gynecological cancer

Survivorship Clinic for long-term survivors with gynecological cancer - Survivorship Clinic / NOGGO-S24

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00028471

Enrollment

360

Registered

2022-03-04

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C56 C57 C48 C55 C53 C57.8 C54

Interventions

Group 1: Intervention Group: Consultation for long-term survivors with gynecologic tumor disease (baseline, follow-up after 6 months, final visit after 12 months) with the following intervention optio

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Initial diagnosis of a gynecologic tumor disease (ovarian, endometrial, or cervical cancer) at least five years ago.

Exclusion criteria

Exclusion criteria: - Insufficient written and spoken German language skills - Individuals who are not capable of giving consent

Design outcomes

Primary

Measure	Time frame
Improvement in health-related quality of life after 12 months compared to baseline. A clinically relevant improvement is defined as an increase in quality of life by at least 6 points in at least one of the two summated scores of the SF-36 (physical or psychological summated score).	—

Secondary

Measure	Time frame
Main clinical secondary endpoints: Cancer-specific quality of life (QLQ-C30), tumor entity-specific quality of life (ovary-28, cervix-24, endometrium-24), health-related quality of life (physical and mental sum score of the SF-36), frequency and severity of long-term side effects (including fatigue, sleep disturbances, depression, polyneuropathy, chemobrain), physical activity, bone density and cardiotoxicity, hand strength, nutritional status and antioxidant status, mortality. All secondary endpoints are assessed at 12 months and in some cases additionally at 3, 6, and 9 months. Main health economic secondary endpoints (secondary data): health care resource utilization before and during intervention (e.g., outpatient physician contacts, inpatient treatments), direct health care costs, indirect costs due to sick days, type and frequency of physician-coded long-term adverse events.	—

Measure

Time frame

Main clinical secondary endpoints: Cancer-specific quality of life (QLQ-C30), tumor entity-specific quality of life (ovary-28, cervix-24, endometrium-24), health-related quality of life (physical and mental sum score of the SF-36), frequency and severity of long-term side effects (including fatigue, sleep disturbances, depression, polyneuropathy, chemobrain), physical activity, bone density and cardiotoxicity, hand strength, nutritional status and antioxidant status, mortality. All secondary endpoints are assessed at 12 months and in some cases additionally at 3, 6, and 9 months. Main health economic secondary endpoints (secondary data): health care resource utilization before and during intervention (e.g., outpatient physician contacts, inpatient treatments), direct health care costs, indirect costs due to sick days, type and frequency of physician-coded long-term adverse events.

—

Countries

Germany

Contacts

Public ContactHannah Woopen

Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie; Charité – Universitätsmedizin Berlin; Campus Virchow-Klinikum

survivorship-clinic@charite.de+49 30 450616507

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026